Serum galectin-3 level predicts early recurrence following successful direct current cardioversion in persistent atrial fibrillation patients. | Zendy

Kadri Murat Gürses | Zendy; Muhammed Ulvi Yalçın | Zendy; Duygu Koçyiğit | Zendy; Hande Canpınar | Zendy; Ahmet Hakan Ateş | Zendy; Uğur Canpolat | Zendy; Hikmet Yorgun | Zendy; Dicle Güç | Zendy; Kudret Aytemir | Zendy

Open Access

Serum galectin-3 level predicts early recurrence following successful direct current cardioversion in persistent atrial fibrillation patients.

Author(s) -

Kadri Murat Gürses,

Muhammed Ulvi Yalçın,

Duygu Koçyiğit,

Hande Canpınar,

Ahmet Hakan Ateş,

Uğur Canpolat,

Hikmet Yorgun,

Dicle Güç,

Kudret Aytemir

Publication year - 2019

Publication title -

turk kardiyoloji dernegi arsivi-archives of the turkish society of cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.2

H-Index - 24

ISSN - 1016-5169

DOI - 10.5543/tkda.2019.58399

Subject(s) - cardiology , medicine , atrial fibrillation , cardioversion , galectin 3

Atrial structural remodeling has been suggested to contribute to atrial fibrillation (AF) recurrence following direct-current cardioversion (DCCV). The role of several inflammatory and extracellular matrix turnover markers in AF recurrence following DCCV has been investigated. However, data on the impact of galectin-3, which is known to play a role in various fibrotic conditions, including cardiac fibrosis are lacking. The aim of this study was to demonstrate the predictive role of serum galectin-3 levels in AF recurrence following successful DCCV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research